Adolor Corp. (ADLR) Making Strides in POI Treatment
The Food and Drug Administration Tuesday night approved Adolor Corp. (ADLR)'s Entereg drug designed to help patients regain gastrointestinal function earlier following bowel resection surgery. The condition the drug was developed to treat, known as postoperative ileus or POI, affects almost all patients undergoing such surgery, and can cause significant discomfort and prolonged hospital stays for patients. Adolor developed the drug in a partnership with GlaxoSmithKline (GSK), the London-based pharmaceutical giant that has a U.S. headquarters in Philadelphia. It is the first product approval for Adolor. "The approval of Entereg in POI represents a major milestone for Adolor, and is…